Aerocrine AB Announces Leadership Changes

Solna (Sweden), June 12 2014 — Aerocrine AB (OMX Nordic Exchange: AERO) today
announced that Marshall Woodworth will be appointed new Chief Financial Officer.
Anders Murman will be promoted to Chief Technology Officer.
Marshall Woodworth will be appointed Chief Financial Officer of Aerocrine, AB,
effective June 13, 2014. The CFO position will be based in Aerocrine’s US-office
in Morrisville, North Carolina and will also have an office in Solna, Sweden.
The leadership change is in alignment with Aerocrine’s strategic direction and
increased focus on key markets such as US. Aerocrine will remain a Swedish
Public Company.

Marshall Woodworth was formerly CFO of Furiex Pharmaceuticals, Inc., a US-based
biotech company that is currently in the process of being acquired by Forest
Laboratories. He has more than 25 years of experience with Initial Public
Offerings (IPO), financial reporting, mergers and acquisitions, fundraising and
corporate finance functions. As CFO, Marshall Woodworth will report to
Aerocrine’s CEO, Scott Myers.

Aerocrine’s current CFO, Michael Colerus, will assist in the transition. Michael
Colerus has served as CFO since 1999 and has been instrumental in establishing
Aerocrine as a commercial stage company and during the transition from a startup
to a publicly listed company as well as during subsequent fundraisings.

Aerocrine is also announcing management changes in Technical Operations. Anders
Murman is promoted to CTO of Aerocrine, effective immediately. Anders Murman has
extensive experience in software & product development within the medical
technology field and is joining Aerocrine from RaySearch Laboratories AB.
Mats Carlson, Aerocrine’s current CTO, is shifting roles to lead Global Business
Development, Alliance Management and Customer Service. Since joining Aerocrine
in 1998, Mats Carlson has led product development and technical operations and
is credited with leading many of the innovations that have formed the basis for
Aerocrine’s products.
Mats Carlson and Anders Murman will report to the CEO. Both will remain based in
Sweden.
For more information, please contact Scott Myers, +46 768 788 379 or +970 368
0336

About Aerocrine:
Aerocrine AB is a medical products company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in technology to monitor and manage airway inflammation, Aerocrine
markets NIOX MINO® and NIOX VERO® (EU). Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on
the Stockholm Stock Exchange in 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 08:55 am on June 12, 2014